The Stop TB Partnership’s Global Drug Facility (GDF) will announce a new initiative to increase access to bedaquiline and delamanid – the two new life-saving medicines recently approved for the treatment of multi-drug resistant tuberculosis (TB). The GDF will share how it is expanding existing and developing new public-private partnerships to expedite and maximize access to these two critical medicines.